References
- 1. Firkin BG, Whitwort JA. Dictionary of medical eponyms. Basel: Roche; 1996.
- 2. Kocić R, Radenković S. Bolesti štitne žlezde [Thyroid disorders]. U: Ilić S, ur. Interna medicina [In: Ilić S, ed. Internal Medicine]. Niš: Medicinski fakultet Niš; 2009. p. 307-19. (Serbian).
- 3. Micić D. Oboljenja štitne žlezde [Thyroid disorders]. U: Klinički centar Srbije, ur. Enciklopedija zdravlja [In Clinical center of Serbia, ed. Encyclopedia of health]. Beograd: Press; 2012. Volume 26.p. 1-4. (Serbian).
- 4. Braun-Falco O, Petzold D. E.M.O. syndrome. Exophthalmoscircumscribed pretibial myxedema-hypertrophic osteoarthropathy. Münchn Med Wochenschr 1967;79:1523-9.
- 5. Georgala S, Katoulis AC, Georgala C, Katoulis EC, Hatziolou E, Stavrianeas NG. Pretibial myxedema as the initial manifestation of Graves’ disease. J Eur Acad Dermatol Venereol 2002;16: 380-3.10.1046/j.1468-3083.2002.00567.x12224697
- 6. Anderson CK, Miller F. Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves’ disease. J Am Acad Dermatol 2003; 48 (6): 970-2.10.1067/mjd.2003.32312789197
- 7. Castineiras I, Del Pozo J, Robles O. Euthyroid nodular pretibial mucinosis: palliative treatment with carbon dioxide laser. Dermatol Surg 2009;35: 719-21.10.1111/j.1524-4725.2009.01115.x19400889
- 8. Şenel E, Güleç AT. Euthyroid pretibial myxedema and EMO syndrome. Acta Dermatovenerol Alp Panonica Adriat 2009;18(1):21-3.
- 9. Fatourechi V. Pretibial myxedema. Pathophysiology and treatment options. Am J Clin Dermatol 2005;6(5):295-309.
- 10. Cannavo SP, Borgia F, Vaccaro M, Guameri F, Magliolo E, Guarneri B. Pretibial myxedema associated with Hashimoto’s thyroiditis. J Eur Acad Dermatol Venereol 2002;16:625-7.10.1046/j.1468-3083.2002.00532.x12482050
- 11. Bahn RS. Pathophysiology of Graves’ ophthalmopathy: The cycle of Disease. J Clin Endocrinol Metab 2003:88(5):1939-45.10.1210/jc.2002-03001012727937
- 12. Fatourechi V, Pajouhi M, Fransway A. Dermopathy of Graves’ disease (pretibial myxedema). Review of 150 cases. Medicine 1994;73:1-7.10.1097/00005792-199401000-000018309359
- 13. Ludgate M, Baker G. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 2002;127:193-8.10.1046/j.1365-2249.2002.01792.x190633811876739
- 14. Heufelder AE, Weetman AP, Ludgate M, Bahn RS. Pathogenesis of Graves’ ophthalmopathy. In: Prummel MF, Wirsinga WM, Mourits MP, eds. Recent developments in Graves’ ophthalmopathy. Dordrecht: Kluwer Academic Publishers; 2000. p. 15-37.10.1007/978-1-4615-4647-4_2
- 15. Daumerie C, Ludgate M, Costagliola S, Many MC. Evidence for thyrotropin receptor immunoreactivity in pretibial connective tissue from patients with thyroid-associated dermopathy. EurEndocrinol 2002;:146:35-8.10.1530/eje.0.146003511751064
- 16. Wolf K, Johnson RA, Suurmond D. Fitzpatrick’ color atlas and synopsis of clinical dematology. 5th ed. New York: McGraw- Hill Professional; 2005. p 443-4.
- 17. Jolles S, Hughes J. Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis and pretibial myxedema. Int Immunopharmacol 2006;6:579-91.10.1016/j.intimp.2005.11.01716504920
- 18. Schwartz KM, Fatourechi V, Ahmed DDF, Pond GR. Dermopathy of Graves’ disease (Pretibial myxedema): long-term outcome. J Clin Endocrinol Metab 2002;87(29):438-46.
- 19. Cho S, Choi J-H, Sung K-J, Moon KC, Koh J-K. Graves’s disease presenting as elephantiasic pretibial myxedema and nodules of the hands. Int J Dermatol 2001;40:276-7.10.1046/j.1365-4362.2001.01108.x11454085
- 20. Schwartz KM, Ahmed DDF, Ahmed I, Fatourechi V. Development of localized myxedema in skin graft. Int J Dermatol 2002;41:401-3.10.1046/j.1365-4362.2002.01535_3.x12121553
- 21. Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, Powell CC, Ahmed DD, Garrity JA. Graves’ dermopathy and acropachy are markers of sever Graves’s ophthalmopathy. Thyroid 2003;13(12):1141-4.10.1089/1050725036073154114751035
- 22. Mack WP, Stasior GO, Cao JH, Stasior OG, Smith TJ. The effect of cigarette smoke constituents on the expression of HLADR in orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Ophthal Plast Reconstr Surg l999;15(4):260-71.10.1097/00002341-199907000-0000710432522
- 23. Weetman AP. Graves’ disease. N Engl J Med 2000;26:1236-48.10.1056/NEJM20001026343170711071676
- 24. Pineda AMM, Tianco EAV, Tan JB, Casintahan FA, Beloso MB. Oral pentoxifylline and topical clobetasol propionate ointment in the treatment of pretibial myxedema, with concomitant improvement of Graves’ ophthalmopathy. J Eur Acad Dermatol Venereol 2007;21:1441-2.10.1111/j.1468-3083.2007.02259.x17958873
- 25. Susser WS, Heermans AG, Chapman MS, Baughman RD. Elephantiasic pretibial myxedema: A novel treatment for an uncommon disorder. J Am Acad Dermatol 2002;46:723-6.10.1067/mjd.2002.11965512004314
- 26. Terheyden P, Kahaly GJ, Zillikens D, Brücher E-B. Lack of rseponse of elephantiasic pretibial myxoedema to treatment with high-dose intravenous immunoglobulins. Clin Exp Dermatol 2003;28:224-6.10.1046/j.1365-2230.2003.01232_3.x12653721
- 27. Felton J, Derrick EK, Price ML. Successful combine surgical and octreotide treatment of severe pretibial myxoedema reviewed after 9 years. Br J Dermatol 2003;148:825-6.10.1046/j.1365-2133.2003.05236.x12752151
- 28. Shinohara M, Hamasaky Y, Katayama J. Refractory pretibial myxedema with response to intralesional insulin-like growth factor 1 antagonist (octreotide): downregulation of hyaluronic acid production by the lesional fibroblasts. Br J Dermatol 2000;143:1083-6. 10.1046/j.1365-2133.2000.03850.x11069527